HOME >> BIOLOGY >> NEWS
Hormone found to reduce appetite by a third

An international team of scientists has discovered a hormone that can significantly decrease the appetite, reducing the amount of food eaten in a day by a third.

The research, published today in Nature, shows how scientists from Imperial College London, with assistance from Oregon Health and Sciences University, USA, and the Garvan Institute of Medical Research, Australia, discovered the novel action of hormone PYY3-36.

PYY3-36 is normally released from the gastro-intestinal tract after eating, in proportion to calorific meal content, telling the brain the body is no longer hungry. When a group of volunteers received artificial infusions of the hormone at normal post-feeding concentrations, their food intake was reduced by a third for a day.

Professor Stephen Bloom, from Imperial College London at the Hammersmith Hospital, comments: "The discovery that PYY3-36 suppresses appetite could be of huge benefit to those struggling with weight problems. With over a billion people across the world now extremely overweight, it is vital this problem is tackled.

"It may be possible to identify foods which cause the release of more PYY3-36, helping to naturally limit appetite, or it may be possible to create a tablet with a similar effect, providing an excellent, natural and safe long term treatment for obesity."

The research was undertaken as part of an ongoing programme at Imperial, looking into how human drives work, of which appetite is an important example.

To test if PYY3-36 is effective, twelve volunteers were infused with either PYY3-36 or saline for ninety minutes in a double blind randomised crossover trial at Hammersmith Hospital, London. Two hours later, the volunteers were offered an unlimited buffet meal.

In the group receiving PYY3-36, average calorific intake dropped by a third over the next 24 hours.

The researchers also looked at how hungry the test group felt both during and after transfusio
'"/>

Contact: Tony Stephenson
at.stephenson@ic.ac.uk
020-7594-6712
Imperial College London
7-Aug-2002


Page: 1 2

Related biology news :

1. Hormone helps fish to mate, may affect human hearing
2. Hormone linked to obesity plays positive role in fertility & possibly male arousal
3. Hormones, sand & terrorism
4. Hormone therapy could help prevent pre-term births
5. Hormones modify the type of proteins produced
6. Hormone replacement therapy may improve breast cancer detection and survival rate
7. Hormone replacement therapy may help prevent heart vessel disease, says Wake Forest researcher
8. Hormone replacement therapy may help prevent chronic wounds in elderly patients
9. Hormone therapy may boost quality of life, say Stanford researchers
10. APS hosts the "Genome and Hormone" Conference
11. Hormone the trigger for fat metabolism; scientists closer to tests in humans

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Hormone found reduce appetite third

(Date:8/26/2015)... The report "Multi-Factor Authentication (MFA) Market ... (Travel & Immigration, Government, Banking, Defense, Commercial Security, Consumer ... published by MarketsandMarkets, Multi-Factor Authentication Market is expected to ... CAGR of 17.7% between 2015 and 2020. ... spread through 169 P ages and ...
(Date:8/24/2015)... CAPE TOWN, South Africa , August 24, 2015 /PRNewswire/ ... awarded Germany ,s largest biometrics manufacturer DERMALOG ... with the "2015 African Biometrics Company of the ... installation in Nigeria .   ... ) and http://www.presseportal.de/nr/8896 - On Thursday ...
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global ... and manufacture of highly valued cardiac markers used in early detection of heart ... protein chemistry has led to the development and commercialization of important cardiac biomarkers ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... and BEIJING , August 26, 2015 ... Scene with Impressive Acheivements  DiaCardio wins 1 st ... The competition, led in Israel ... featured 21 startups from countries including the US, China ... and Latin America .  Impressive ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
Cached News: